Cytek Biosciences Stock In The News

CTKB Stock  USD 4.38  0.07  1.62%   
Our overall analysis of Cytek Biosciences' news coverage and content from conventional and social sources shows investors' bearish mood towards Cytek Biosciences. The specific impact of Cytek Biosciences news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Cytek Biosciences' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Cytek Biosciences headlines in addition to utilizing other, more conventional financial analysis modules. Check out Cytek Biosciences Backtesting and Cytek Biosciences Hype Analysis.
For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.

Cytek Biosciences Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
https://www.globenewswire.com/news-release/2025/02/13/3026284/0/en/Cytek-Biosciences-to-Report-Fourth-Quarter-and-Full-Year-2024-Financial-Results-on-February-27-2025.html
 Neutral
Macroaxis News: globenewswire.com
Cytek Biosciences to participate in the Piper Sandler 35th Annual Healthcare Conference
https://www.globenewswire.com/news-release/2023/11/14/2780509/0/en/Cytek-Biosciences-to-participate-in-the-Piper-Sandler-35th-Annual-Healthcare-Conference.html
 Neutral
Macroaxis News: globenewswire.com
Cytek® Aurora™ CS System Wins BioTech Breakthrough Award for ‘Cell Sorting Product of the Year’
https://www.globenewswire.com/news-release/2023/11/08/2776319/0/en/Cytek-Aurora-CS-System-Wins-BioTech-Breakthrough-Award-for-Cell-Sorting-Product-of-the-Year.html
 Bullish
Macroaxis News: globenewswire.com
Cytek Biosciences Reports Third Quarter 2023 Financial Results
https://www.globenewswire.com/news-release/2023/11/07/2775619/0/en/Cytek-Biosciences-Reports-Third-Quarter-2023-Financial-Results.html
 Bullish
Macroaxis News: globenewswire.com
Cytek Biosciences to Report Third Quarter 2023 Financial Results on November 7, 2023
https://www.globenewswire.com/news-release/2023/10/19/2763685/0/en/Cytek-Biosciences-to-Report-Third-Quarter-2023-Financial-Results-on-November-7-2023.html
 Neutral
Macroaxis News: globenewswire.com
Cytek® Biosciences Achieves ISO 13485 Certification at Headquarters
https://www.globenewswire.com/news-release/2023/09/27/2750427/0/en/Cytek-Biosciences-Achieves-ISO-13485-Certification-at-Headquarters.html
 Neutral
Macroaxis News: globenewswire.com
Cytek Biosciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
https://www.globenewswire.com/news-release/2023/09/20/2746863/0/en/Cytek-Biosciences-to-Participate-in-the-2023-Cantor-Fitzgerald-Global-Healthcare-Conference.html
 Neutral
Macroaxis News: globenewswire.com
Cytek® Biosciences Cell Analysis Solutions Take Center Stage at Upcoming Clinical Conferences in the US and Europe
https://www.globenewswire.com/news-release/2023/09/20/2746504/0/en/Cytek-Biosciences-Cell-Analysis-Solutions-Take-Center-Stage-at-Upcoming-Clinical-Conferences-in-the-US-and-Europe.html
 Bullish
Macroaxis News: globenewswire.com
Cytek® Biosciences Launches Educational Roadshow Focused on Spectral Flow Cytometry
https://www.globenewswire.com/news-release/2023/09/14/2743290/0/en/Cytek-Biosciences-Launches-Educational-Roadshow-Focused-on-Spectral-Flow-Cytometry.html
 Bullish
Macroaxis News: globenewswire.com
Cytek Biosciences to participate in the Morgan Stanley 21st Annual Global Healthcare Conference
https://www.globenewswire.com/news-release/2023/09/06/2738857/0/en/Cytek-Biosciences-to-participate-in-the-Morgan-Stanley-21st-Annual-Global-Healthcare-Conference.html
 Bullish

Cytek Biosciences Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Cytek and other traded companies coverage with news coverage. We help investors stay connected with Cytek headlines for the 5th of March to make an informed investment decision based on correlating the impacts of news items on Cytek Stock performance. Please note that trading solely based on the Cytek Biosciences hype is not for everyone as timely availability and quick action are needed to avoid losses.
Cytek Biosciences' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Cytek Biosciences investors visualize upcoming and past events in order to time the market based on Cytek Biosciences noise-free hype analysis.
Cytek Biosciences stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Cytek earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Cytek Biosciences that are available to investors today. That information is available publicly through Cytek media outlets and privately through word of mouth or via Cytek internal channels. However, regardless of the origin, that massive amount of Cytek data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cytek Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cytek Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cytek Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cytek Biosciences alpha.

Cytek Largest EPS Surprises

Earnings surprises can significantly impact Cytek Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-05-08
2024-03-31-0.04-0.05-0.0125 
2023-02-28
2022-12-310.050.060.0120 
2022-08-10
2022-06-300.020.030.0150 
2024-12-31
2024-12-310.10330.11550.012211 
2024-11-06
2024-09-300.03670.05580.019152 
2022-11-09
2022-09-300.020.040.02100 
View All Earnings Estimates

Cytek Biosciences Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Cytek Biosciences Stock. Current markets are strongly bearish. About 89% of major world exchanges and indexes are down. See today's market update for more information.
news
4th of March 2025
Versor Investments LP Acquires Shares of 47,000 Cytek Biosciences, Inc.
at thelincolnianonline.com 
Gurufocus Stories at Macroaxis
28th of February 2025
Q4 2024 Cytek Biosciences Inc Earnings Call Transcript
at gurufocus.com 
Macroaxis News: globenewswire.com
27th of February 2025
Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides...
at globenewswire.com 
Macroaxis News
25th of February 2025
Disposition of 8840 shares by Paul Williams of Cytek Biosciences subject to Rule 16b-3
at MacroaxisInsider 
Macroaxis News
18th of February 2025
Disposition of 6758 shares by Wenbin Jiang of Cytek Biosciences subject to Rule 16b-3
at MacroaxisInsider 
Gurufocus Stories at Macroaxis
13th of February 2025
Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on Februar...
at gurufocus.com 
Google News at Macroaxis
31st of January 2025
Goldman Sachs cuts Cytek Biosciences stock rating to sell - Investing.com
at news.google.com 
Google News at Macroaxis
27th of January 2025
Cytek Biosciences, Inc. is largely controlled by institutional shareholders who own 53 per...
at news.google.com 
Gurufocus Stories at Macroaxis
15th of January 2025
Cytek Biosciences Announces Preliminary Full Year 2024 Revenue Results
at gurufocus.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cytek Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cytek Biosciences' short interest history, or implied volatility extrapolated from Cytek Biosciences options trading.
When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:
Check out Cytek Biosciences Backtesting and Cytek Biosciences Hype Analysis.
For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.735
Earnings Share
(0.05)
Revenue Per Share
1.535
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.03)
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.